A sample of 491 digital health companies on R2GConnect were collected to conduct an analysis, highlighting external funding distribution by different solution types over the last decade 2015-2024. Some notable highlights:
-
Diagnostics & Detection (21%): Nearly 6.5 Billion USD has been invested in companies providing with a advanced diagnosis device, AI-based applications and cloud-based software. Innovations in these tools are designed to improve the speed and accuracy of diagnoses pathway, while also reducing costs, applying in various therapeutic areas such as oncology, inflammatory, cardiovascular, fertility and infectious disease. Due to the complexity in developing the tools, the investment ticket size is larger than other solution types.
-
Digital therapeutics & Biomarker (10%): Over 3.1 Billion USD has been directed to DTx platforms and VR device that use augmented reality, gameplay and artificial intelligence to deliver rehabilitation and health treatment. These solutions primarily offer assistance in mental health, neurology, wellness, diabetes and metabolic disorders.
-
Data Analytics and AI (7%): Investment ticket size in Data Analytics is appeared to be smaller than the above solution types (usually less than 5 Million per company). In total, investors have funded more than 2 Billion USD in companies that apply AI/ML into their solutions, particularly increasing around the time of AI boom 2021.
-
Other key solution types including Disease management, Telehealth / Telemedicine, Medical device / wearable, Self management, Clinical Trial & Research, RPM, Care coordination fluctuate from 4% to 6%, with the total investment of more than 1 Billion USD allocated to each category over the past ten year.